Target intelligence / Profile preview

Complement system (via mannose-binding lectin-associated serine proteases activation) (null)

Target
null
Molecular classification
Enzyme (specifically, serine protease), Component of the complement system, Lectin pathway molecule, Other: Multi-protein complex (if referring to the full complement pathway rather than a specific MASP)
01

Overview

The complement system is a critical component of the innate immune response, with three major activation pathways: classical, lectin, and alternative. The mannan-binding lectin–associated serine proteases (MASPs)—especially MASP-1, MASP-2, and MASP-3—are serine protease enzymes that mediate the lectin pathway, serving as key activators upon recognition of pathogen-associated ligands. Specifically, MASP-2 cleaves C4 and C2 to generate C3 convertase, driving formation of downstream effector complexes, while MASP-1 and MASP-3 regulate this pathway and can also activate the alternative pathway indirectly by activating complement factor D[1][3][4][5]. Dysregulation of MASPs or aberrant lectin pathway activity is implicated in a range of inflammatory and autoimmune diseases, and they are emerging as potential therapeutic targets for complement-driven pathology. For structured data systems, it is preferable to list the individual MASPs (MASP-1, MASP-2, MASP-3) as explicit targets rather than the vague “complement system via MASPs activation.”

Other names
Lectin pathway of complement activationMannan-binding lectin–associated serine proteases (MASPs) pathwayMASP-1, MASP-2, MASP-3
02

Mechanism of action

Inhibition of MASP-2: Blocks cleavage of C4 and C2, preventing lectin pathway activation and downstream complement cascade. Inhibition of MASP-3: Prevents activation of complement factor D, reducing alternative pathway activity.

03

Biological functions

Immune response (innate immunity)Pathogen recognition and eliminationOpsonization (marking pathogens)Cell lysis (via membrane attack complex assembly)Regulation of inflammation
04

Disease associations

Inflammation (excessive or dysregulated activation can cause/reinforce inflammatory diseases)Infection (deficiency increases susceptibility; overactivation can cause damage)Autoimmune disease (e.g., lupus, atypical hemolytic uremic syndrome)Cardiovascular disease (through inflammation and thrombosis association)Other: Angioedema, age-related macular degeneration
05

Safety considerations

Infection risk: Suppression of host innate immunity increases risk of bacterial, viral, and fungal infectionsImmune complex disease: Potential for immune dysregulationOff-target effects: Lectin pathway shares effectors with other complement pathways, so broad complement suppression may occur
06

Interacting drugs

Narsoplimab (OMS721; anti-MASP-2 monoclonal antibody, under investigation for aHUS and thrombotic microangiopathies)

1 more in the full profile.

07

Biomarkers

Serum MASP-2/MASP-3 levels (under investigation)Complement activity assays (lectin pathway-specific hemolytic assay, CH50/ELISA-derived reagents)C4, C2, and C3 cleavage fragments to monitor pathway inhibition/effectiveness

Beyond the preview

Go deeper on Complement system (via mannose-binding lectin-associated serine proteases activation) (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement system (via mannose-binding lectin-associated serine proteases activation) (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call